Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03003533 · ClinicalTrials.gov registry record · Phase 1
A Gene Transfer Study for Hemophilia A
A Phase 1 study, sponsored by Spark Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03003533 is a Phase 1 study that has completed, run by Spark Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT03003533, a Phase 1 study, has completed, sponsored by Spark Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with hemophilia A.
Interventions
- GENETIC SPK-8011
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-01-26 |
| Est. Completion | 2023-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03003533
The ClinicalTrials.gov registry entry for NCT03003533 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spark Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPK-8011 is the first listed.
NCT03003533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03003533 about?
NCT03003533 is a clinical study titled "A Gene Transfer Study for Hemophilia A". This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with hemophilia A.
What is the current status of trial NCT03003533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2017-01-26. Estimated completion is 2023-12-05.
What interventions are being tested in trial NCT03003533?
The interventions under investigation include: SPK-8011 (GENETIC).
Who is sponsoring clinical trial NCT03003533?
This trial is sponsored by Spark Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.